CRISPR Therapeutics

CRISPR Therapeutics is, quite literally, the company that brought gene editing from science fiction to reality. They co-developed the first-ever CRISPR-based medicine approved anywhere in the world — Casgevy, a one-time treatment for sickle cell disease and a blood disorder called beta-thalassemia. Here's how it works in simple terms: they take a patient's own blood stem cells out of their body, use CRISPR gene editing scissors to fix the genetic defect, and put them back. The edited cells then produce healthy hemoglobin for what appears to be the rest of the patient's life. It's as close to a cure as medicine has ever gotten for these diseases. For investors, the big questions right now are commercial ones, not scientific ones. Casgevy works — we know that. The question is whether enough patients can actually access a treatment that requires weeks of hospitalization and harsh pre-conditioning chemotherapy. Revenue ramp speed is everything. Beyond Casgevy, CRISPR is working on something potentially much bigger: off-the-shelf cancer cell therapies. Current CAR-T treatments like Yescarta require custom-manufacturing each dose from the patient's own cells, which takes weeks and costs $400K+. If CRISPR can make a universal version using gene-edited donor cells, it could dramatically expand who can be treated. They're also quietly working on what could be a cure for Type 1 diabetes using gene-edited insulin-producing cells — extremely early but the ultimate homerun if it works. With $4.2 billion in cash, CRISPR can fund everything in their pipeline for years without raising money. The stock trades well below that cash value plus Casgevy's projected revenues, which means the market is essentially giving you the entire pipeline for free.